A Phase 1 Dose Escalation and Expansion Trial of the Next-Generation Oral SERD Camizestrant in Women with ER-positive, HER2-negative Advanced Breast Cancer: SERENA-1 Monotherapy Results

E. Hamilton, M. Oliveira,N. Turner,J. Garcia-Corbacho, C. Hernando,E. M. Ciruelos, P. Kabos,M. Ruiz-Borrego, A. Armstrong, M. R. Patel,C. Vaklavas, C. Twelves, V. Boni, J. Incorvati,T. Brier, L. Gibbons,T. Klinowska,J. P. O. Lindemann,C. J. Morrow, A. Sykes, R. D. Baird

Annals of oncology official journal of the European Society for Medical Oncology（2024）

Cited 0|Views6

Key words

next-generation oral SERD,camizestrant,ER+HER2-breast cancer

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined